CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

Published:2013-12-19 Issue:26 Volume:122 Page:4253-4258
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Johnson Gillian G.¹²,Lin Ke¹²,Cox Trevor F.²,Oates Melanie²,Sibson David R.²,Eccles Richard²,Lloyd Bryony²,Gardiner Laura-Jayne²,Carr Daniel F.³,Pirmohamed Munir³,Strefford Jonathan C.⁴,Oscier David G.⁵,Gonzalez de Castro David⁶,Else Monica⁶,Catovsky Daniel⁶,Pettitt Andrew R.²

Affiliation:

1. Directorate of Blood Sciences, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK;

2. Department of Molecular and Clinical Cancer Medicine and

3. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK;

4. Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK;

5. Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK; and

6. Haemato-oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, UK

Abstract

Key Points Therapeutic response in CLL can be influenced by host pharmacogenetics.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/26/4253/1372576/4253.pdf

Reference34 articles.

1. Chronic lymphocytic leukemia.;Chiorazzi;N Engl J Med,2005

2. From pathogenesis to treatment of chronic lymphocytic leukaemia.;Zenz;Nat Rev Cancer,2010

3. Prognostic factors in chronic lymphocytic leukemia-what do we need to know?;Cramer;Nat Rev Clin Oncol,2011

4. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.;Gonzalez;J Clin Oncol,2011

5. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia.;Trbusek;J Clin Oncol,2011

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine: Dose for anticancer therapy;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

2. Genotype influenced pharmacokinetics of anticancer medicine: A connecting link;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

3. Rosmarinic acid improves cyclophosphamide-induced immunosuppression in mice by immunomodulatory and antioxidant effects;Food Bioscience;2023-12

4. Genetic polymorphisms effect on cyclophosphamide’s tolerability and clinical efficacy in Egyptian patients with lupus nephritis;Pharmacogenetics and Genomics;2023-08-24

5. Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens;Best Practice & Research Clinical Haematology;2023-06